Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
M&A Deal

Silence Therapeutics Shares Skyrocket 125% After Merck KGaA to Acquire It for $1.3 Billion

Merck KGaA to Acquire Silence Therapeutics for $1.3 Billion in All-Cash Deal

+125.58% $8.68 when we broke this story → $19.58 at 9:34 AM ET, 19 Oct 2026

Silence Therapeutics (SLN) has entered into a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany, for an equity value of approximately $1.3 billion. The acquisition aims to integrate Silence's proprietary siRNA technology and lead clinical assets into Merck KGaA's rare disease and specialty medicine portfolio.

Silence Therapeutics Shares Skyrocket 125% After Merck KGaA to Acquire It for $1.3 Billion
Silence Therapeutics plc · Healthcare · Representative image
Key numbers
Deal value$1.3B
Share of market cap105.7%
Share of annual revenue232558.1%

Key highlights

  • Shareholders to receive $20.00 per American Depositary Share in cash, representing a 130% premium
  • Total transaction value estimated at $1.3 billion equity value and $1.1 billion enterprise value
  • Acquisition focuses on Divesiran, a Phase 2 siRNA candidate for polycythemia vera
  • Deal to be executed via a U.K. scheme of arrangement with expected closure in Q1 2027
  • Shareholders representing 14% of voting power have already committed to supporting the transaction

What Is the Deal?

Merck KGaA, Darmstadt, Germany, will acquire all issued and to be issued share capital of Silence Therapeutics for $6.6667 per ordinary share, translating to $20.00 per American Depositary Share (ADS). The transaction is structured as an all-cash acquisition valuing the biotechnology firm at approximately $1.3 billion. Subject to approval by Silence shareholders and the High Court of Justice of England and Wales, the deal is expected to conclude in the first quarter of 2027. Regulatory clearances are required under the Hart-Scott-Rodino Act in the United States and German antitrust regulations before the transfer is finalized.

Silence Therapeutics plc share price · last month
Line chart of Silence Therapeutics plc's share price over the last month, from $19.58 on 19 Oct → $19.80 on 16 Nov; our story on 19 Oct at $8.68.

Up 128.1% since our story on 19 Oct: $8.68 when we broke it → $19.80 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$19.58
20 Oct$19.61
21 Oct$19.67
22 Oct$19.66
23 Oct$19.67
26 Oct$19.78
27 Oct$19.78
28 Oct$19.71
29 Oct$19.80
30 Oct$19.75
2 Nov$19.76
3 Nov$19.78
4 Nov$19.80
5 Nov$19.72
6 Nov$19.73
9 Nov$19.75
10 Nov$19.79
11 Nov$19.77
12 Nov$19.80
13 Nov$19.83
16 Nov$19.80

Deal Structure & Terms

  • Consideration is 100% cash with no stock-based components or earnout provisions disclosed
  • Offer represents an 82% premium to the 30-day volume-weighted average price of $10.99
  • Transaction requires 75% shareholder approval by value at the upcoming Scheme Meeting
  • Silence ADSs will be delisted from the Nasdaq Stock Market following the effective date
  • Specific securityholders have entered voting and support agreements for 14% of voting securities

Strategic Rationale

The acquisition is designed to strengthen Merck KGaA's specialty and rare disease pipeline, specifically through the addition of Divesiran. Divesiran is a Phase 2 siRNA candidate currently being evaluated for the treatment of polycythemia vera, a rare blood cancer. Merck KGaA intends to leverage its global scale and commercial resources to accelerate Divesiran’s transition into Phase 3 clinical development. This move follows Merck KGaA's previous acquisition of SpringWorks Therapeutics, signaling a continued commitment to expanding its presence in targeted medical fields with high unmet needs using external innovation.

Business Overview

Silence Therapeutics is a London-based clinical-stage biotechnology company that specializes in precision-engineered medicines using its proprietary siRNA platform. The company's technology is designed to inhibit the expression of specific disease-causing genes in the liver. While Silence recently reported a cash runway extending into 2029, it remains in the pre-revenue stage typical of clinical biotech firms. The company’s pipeline focuses on hematology and cardiovascular diseases, with its lead program SANRECO (Divesiran) preparing for a pivotal Phase 3 trial initiation in the first half of 2027.

Industry Landscape

This deal underscores the ongoing consolidation in the biopharmaceutical sector, where large-cap entities seek to acquire de-risked Phase 2 and Phase 3 assets to bolster their future growth. The siRNA modality has gained significant traction as a validated therapeutic approach, drawing interest from major pharmaceutical players looking to diversify their platforms. By incorporating Silence's assets, Merck KGaA competes more directly with other RNA-interference specialized companies. This transaction highlights the premium value currently placed on late-stage biotech assets that address rare diseases with limited existing treatment options.

Management commentary

“We are pleased to have reached this agreement with Merck KGaA, Darmstadt, Germany, which is the result of a competitive sale process and delivers significant, immediate and certain value to our shareholders.”

Iain Ross, Interim Principal Executive Officer and Chairman of the Silence Board

“The planned acquisition of Silence Therapeutics will strengthen our capabilities to serve patients with targeted specialty and rare diseases.”

Kai Beckmann, Chairman of the Executive Board and Group CEO of Merck KGaA, Darmstadt, Germany
Silence Therapeutics plc · financial snapshot
Share price$8.68
Market cap$1.2B
Revenue (annual)$559,000
1-month price change-30.56%
SectorHealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by Silence Therapeutics plc announcing a definitive agreement to be acquired by Merck KGaA.

Read the filing ↗

Track Silence Therapeutics plc live

Get the next Silence Therapeutics plc SEC filing seconds after it lands.

More in M&A & Deals

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.